Role of <i>IL6R</i> Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by chronic arthritis that may lead to irreversible joint damage and significant disability. Patients with RA are commonly treated with Tocilizumab (TCZ), an IL-6 receptor (IL-6R) antagonist, but many patients refractorily resp...
Main Authors: | Luis Sainz, Pau Riera, Patricia Moya, Sara Bernal, Jordi Casademont, Cesar Díaz-Torné, Ana Milena Millán, Hye Sang Park, Adriana Lasa, Héctor Corominas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/9/1942 |
Similar Items
-
Clinical Value of <i>IL6R</i> Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis
by: Luis Sainz, et al.
Published: (2022-12-01) -
Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01) -
RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01) -
Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study
by: Suhel Gabriele Al Khayyat, et al.
Published: (2022-11-01) -
The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis
by: Sheng-Xiao Zhang, et al.
Published: (2024-04-01)